Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/45996
metadata.artigo.dc.title: | Remdesivir therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
metadata.artigo.dc.creator: | Reddy Vegivinti, Charan Thej Pederson, John M. Saravu, Kavitha Gupta, Nitin Barrett, Averi Davis, Amber R. Kallmes, Kevin M. Evanson, Kirk W. |
metadata.artigo.dc.subject: | COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antiviral agents |
metadata.artigo.dc.publisher: | Elsevier |
metadata.artigo.dc.date.issued: | Feb-2021 |
metadata.artigo.dc.identifier.citation: | REDDY VEGIVINTI, C. T. et al. Remdesivir therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Annals of Medicine and Surgery, [S.l.], v. 62, p. 43-48, Feb. 2021. |
metadata.artigo.dc.description.abstract: | Purpose To perform a systematic review and meta-analysis of randomized controlled trials that examined remdesivir treatment for COVID-19. Materials and methods A systematic literature search was performed using Pubmed, Embase, and ClinicalTrials.gov to identify studies published up to October 25, 2020 that examined COVID-19 treatment with remdesivir. A total of 3 randomized controlled trials that consisted of 1691 patients were included in the meta-analysis. Results The odds for mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) following treatment was significantly lower in the remdesivir group compared to the control group (OR = 0.48 [95% CI: 0.34; 0.69], p < 0.001). The odds of early (at day 14/15; OR = 1.42 [95% CI: 1.16; 1.74], p < 0.001) and late (at day 28/29; OR = 1.44 [95% CI: 1.16; 1.79], p = 0.001) hospital discharge were significantly higher in the remdesivir group compared to the control group. There was no difference in the odds for mortality in patients treated with remdesivir (OR = 0.77 [95% CI: 0.56; 1.06], p = 0.108). Conclusions Remdesivir attenuates disease progression, leading to lower odds of MV/ECMO and greater odds of hospital discharge for COVID-19 patients. However, remdesivir does not affect odds of mortality. |
metadata.artigo.dc.identifier.uri: | https://www.sciencedirect.com/science/article/pii/S2049080120305689 http://repositorio.ufla.br/jspui/handle/1/45996 |
metadata.artigo.dc.language: | en_US |
Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.